
    
      Single centre, open-label, multiple doses, one-sequence design study in two parallel groups
      of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending
      doses of Topamax (TPM) in last phases; Group B: Pre-treatment with TPM, treatment with TPM
      and ascending doses of ESL in last phases
    
  